Adams J, Elliott PJ (2000) New agents in cancer clinical trials. Oncogene 19:6687–6692New agents in cancer clinical trials - Adams, Elliott - 2000 () Citation Context ...iversity on M arch 6, 2014 http://toxsci.oxfordjournals.org/ D ow nloaded from suitability for further development ...
Credit: Pixabay/CC0 Public Domain Despite widespread agreement that clinical trials should enroll a representative sampling of individuals from different age, gender, and racial and ethnic groups, a new Yale School of Medicine study shows that clinical trials on new cancer drugs still fall far short...
Considering the clinical bottleneck of poor response to conventional treatment as an opportunity, the basket trial identified the qualitative and quantitative proliferation-driven ability of the molecular phenotype in different tumor species and extended its application to pan-cancer. In contrast to traditio...
Traditionally, cisplatin-based chemotherapy has been thestandard treatmentfor bladder cancer patients who are able to tolerate this drug. However, responses have been limited, and durable outcomes rare. Over the past years, two phase-3clinical trialsstudied the effects of combining immunotherapy with e...
J. Precision oncology: A new era of cancer clinical trials. Cancer Lett, doi: 10.1016/j. canlet.2016.03.015 (2016).Renfro LA, An M-W, Mandrekar SJ (2016) Precision oncology: a new era of cancer clinical trials. Cancer Lett 387:121-126...
The two-step process also appeared to help with cell memory. In CAR T-cell therapy, boosting these memory properties helps T cells better recognize and combat cancer over time. In recent studies using T cells grown with the lab's new approach, 63% of patients experienced a partial or compl...
universal-RAS/RAF medicines for broad populations of cancer patients, recently announced positive initial response data from the first five patients treated with IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in first line pancreatic cancer as part of its ongoing Phase 2a clinical ...
Insufficient patient enrollment per month (=accrual) is the leading cause of cancer trial termination. To identify and quantify factors associated with pat
The TARGIT-A trial reported risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy for breast cancer to be as effective as whole-breast external beam radiotherapy (EBRT). Here, we present further detailed analyses. Methods In total, 2298 women (≥45 years, invasive duct...
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003;349(1):17-26. doi:10.1056/NEJMoa030684PubMedGoogle ScholarCrossref 41. Wong CH, Siah KW, Lo AW. Estimation of clinical trial ...